Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 5.21% |
| CYNOSURE INC | CYNO | 4.42% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
| BLOOMIN' | BLMN | 2.93% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, DaVita Inc. ( DVA - Analyst Report ) announced the acquisition of Tulips Dialysis Centre – a hemodialysis center near Kuala Lumpur in Malaysia. Additionally, the company opened two dialysis centers in the greater Kuala Lumpur area as a joint venture with Seri Setia Group. The financial and other terms of the acquisition as well as the joint venture were not divulged.
Tulips Dialysis Centre is operating with 10 stations in Kota Damansara, which is situated 20 kilometers east of Kuala Lumpur. Meanwhile, the new centers have been opened in central Kuala Lumpur and Selangor with 19 and 6 stations, respectively.
DaVita is slowly expanding in international markets along with growing domestically through acquisitions and alliances. In the first nine months of 2012, DaVita acquired 71 dialysis centers, opened 48 centers and merged or sold 8 centers in the U.S., while 10 centers were acquired or opened outside the U.S.
DaVita has ventured into Saudi Arabia, China, India and Germany over the past two years. The company purchased a controlling interest in a Saudi Arabian kidney care company – Lehbi Care, announced a joint venture with 3SBio Inc. ( SSRX - Snapshot Report ) , a China-based biotechnology company and increased its stake in NephroLife, an India-based kidney care company, so far in 2012. Further, in November 2011, the company acquired ExtraCorp, a German company that owns two dialysis centers and manages two others.
Domestically, DaVita acquired ModernMed in January 2012 and DSI Renal Inc. in September 2011. Additionally, the company merged with HealthCare Partners in November 2012, which will support and augment its primary care and specialty physician services as well as hospital and other healthcare services.
DaVita seeks to expand its presence internationally and has been looking for acquisition and partnership opportunities in all major European and Asian countries. We expect that the company will involve itself in more meaningful mergers and acquisitions in the near future, given its strong international reputation that provides competitive advantage in terms of global acquisitions.
DaVita currently carries a Zacks #3 Rank (short-term Hold).
Read the full Analyst Report on DVA
Read the full Snapshot Report on SSRX